

# Redefining the **Future of Cancer Treatment**

We are a team of passionate scientists, visionary entrepreneurs, and innovators united around our mission to redefine the future of cancer treatment. **Our goal is to help people facing cancer live longer, better lives. Our hope is fueled by the dream of a future free from cancer.**



## Addressing the unmet medical needs of **cancer patients**



### **SPEED**

Speed is critical for **cancer patients who cannot afford to wait to receive treatment**



### **URGENCY**

Urgent need for **effective, broadly accessible treatment options and novel therapies** is paramount



*“Tomorrow, our dream of a future free from cancer fuels our passion, motivation, and hope. We are determined to redefine the future of cancer treatment.”*

**Paul Stoffels\***  
CEO and Chairman

## **Our focus** in oncology

We focus on delivering more years of life and improving the quality of life for people living with cancer. Our current work is focused on the following hematological cancers for patients in need of additional and improved treatment options:



**Non-Hodgkin's lymphoma (NHL)<sup>1</sup>**



**Chronic lymphocytic leukemia (CLL)<sup>1</sup>**




**Multiple myeloma (MM)<sup>1</sup>**

<sup>1</sup>Unapproved indications of Galapagos research

\* Dr. Paul Stoffels, acting via Stoffels IMC BV

# Today, our unwavering commitment lies in accelerating new ways to target cancer from different angles

We believe that by partnering with innovators both inside and outside our organization, we can introduce a new, multi-faceted cancer treatment paradigm aimed at addressing high unmet medical needs.



## Novel manufacturing technology

**WE ARE COMMITTED TO MANUFACTURING PERSONALIZED CANCER CELL THERAPIES AT THE POINT-OF-CARE, RIGHT WHERE PATIENTS ARE**



### Novel point-of-care supply model

Galapagos' decentralized point-of-care CAR-T manufacturing model, consists of a proprietary xCellit® workflow management and monitoring software, a manufacturing platform for cell therapies (using Lonza's Cocoon®) and a proprietary quality control (QC) testing and release strategy



### Greater physicians oversight

Enable clinicians to administer fresh CAR T cells without complex logistics or cryopreservation and provides greater oversight for physicians during the process



### Faster solutions for patients

Ability to reduce the average vein-to-vein (i.e. time between T-cell collection and CAR-T infusion) time from months to days

We are determined to translate groundbreaking science into innovative medicines and work towards a cancer-free world, **tomorrow**

We aim to leverage our research, development, and manufacturing capabilities to rapidly address more unmet needs in oncology, including solid tumors. Through our collective expertise, we are determined to shift the treatment paradigm of cancer.

Let's work towards a brighter tomorrow  
at [glpg.com/oncology](http://glpg.com/oncology)

**TOGETHER WE ARE  
LIVING INNOVATION**

#### Company headquarters

Generaal De Wittelaan L11 A3  
2800 Mechelen, Belgium  
Tel: +32 15 34 29 00



[www.glpg.com](http://www.glpg.com)



GalapagosGlobal



Galapagos

**Galapagos**